| ○ |
|
北島 政樹 |
国際医療福祉大学 学長 |
| 一般消化器外科、上部消化管、臓器移植、内視鏡外科（ロボット手術を含む） 、がんの臨床・ 基礎研究、医療機器開発 |
Surgical Treatment of Esophageal Cancer - The Advent of the Era of individualization .
Masaki Kitajima, Yuko Kitagawa
The New England Journal of Medicine,
November 2002,347(21),1705-1708
|
Langenbeck’s Archives-an international communication forum between Japanese and German surgeons
Masaki Kitajima,Yoshiki Hiki
Langenbecks Archives of Surgery,April 2010,395(1),57-67
|
Sentinel Nobe Mapping for Gastric Cancer :A Prospective Multicenter Trial in Japan
Y Kitagawa,H Takeuchi,Y Takagi,S Natsugoe,M Terashima,N Murakami,T Fujimuea,H Tsujimoto,H Hayashi,N Yoshimizu,A Takagane,Y Mohri,K Nabeshima,Y Uenosono,S Kinami,J Sakamoto,S Morita,T Aikou,K Miwa and M Kitajima
JOURNAL of Clinical ONCOLOGY,Sep2013,31(29),3704-3710
|
|
| |
|
長村 義之 |
国際医療福祉大学 大学院教授
国際医療福祉大学 病理診断センター長 |
| 病理学、内分泌学、腫瘍学 |
| Masubuchi T, Tada Y, Maruya SI, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T : Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 2015,20:35-44. |
| Hanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penau lt-Llorca F, van de Vijver M, Viale G:HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 2014, 27:4-18. |
Sawai T, Uzuki M, Miura Y, Kamataki A, Matsumura T, Saito K, Kurose A, Osamura YR, Yoshimi N, Kanno H, et al: World's first telepathology experiments employing WINDS ultra-high-speed internet satellite, nicknamed "KIZUNA". J Pathol Inform 2013,4 :24.
|
|
| |
|
児玉 哲郎 |
栃木県立がんセンタ-名誉所長 |
| 臨床腫瘍学、呼吸器診断学 |
Characteristics of subsolid pulmonary nodules showing growth during follow-up with CT scanning. Matsuguma H, Mori K, Nakahara R, Suzuki H, Kasai T, Kamiyama Y, Igarashi S, Kodama T, Yokoi K. Chest 2013;143:436-443.
|
| Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Sugano K, Nakamura S, Ando J, Takayama S, Kamata H, Sekiguchi I, Ubukata M, Kodama T, Arai M, Kasumi F, Hirai Y, Ikeda T, Jinnno H, Kitajima M, Aoki D, Hirasawa A, Takeda Y, Yazaki K, Fukutomi T, Kinoshita T, Tsunematsu R, Yoshida T, Izumi M, Umezawa S, Yagata H, Komatsu H, Arimori N, Matoba N, Gondo N, Yokoyama S, Miki Y:. Cancer Sci 2008; 99:1967-1976 |
| Randomized pharamakokinetic and pharamakodynamic study of docetaxel: Dosing based on body-surface area compared with indivisualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous crtisol. Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N, Saijo N. J Clin Oncol, 2005;23:1061-1069 |
|
| |
|
田村 和夫 |
福岡大学医学部腫瘍・血液・感染症内科学 教授 |
| 内科学、臨床腫瘍学、血液学 |
Prospective randomized study of cefepime, panipenem, or meropenem
monotherapy for patients with hematological disorders and febrile
neutropenia. Nakagawa Y, Suzuki K, Ohta K, Hino M, Ohyashiki K,
Kanamaru A, Tamura K, Urabe A, Masaoka T, the Japan Febrile Neutropenia
Study Group J Infect Chemother 19:103-111, 2013
|
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy
for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Takamatsu Y, Sunami K, Muta T, Morimoto H, Miyamoto T, Higuchi M,
Uozumi K, Hata H, Tamura K; Kyushu Hematology Organization for
Treatment Study Group (K-HOT). Int J Hematol 98(2):179-85, 2013
|
Empirical voriconazole therapy for febrile neutropenic patients with
hematological disorders: a prospective multicenter trial in Japan. Koh H,
Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N,
Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A,
Masaoka T. J Infect Chemother. 19(6):1126-34, 2013
|
|
| |
|
高嶋 成光 |
NHO四国がんセンター 名誉院長 |
| 乳腺外科 |
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:A randomized,placebo-controlled trial. Kohno N, Aogi K,Takashima S,et al. J Clin Oncol 23:3314-3321,2005.
|
Randomized trial of cyclophosphamide,epirubicin,and fluorouracil chemotherapy compared with cyclophosphamide,methotrexate,and fluorouracil with node-positive breast cancer in Japan. Kimura M,
Tominaga Y, Takashima S,et al. Breast Cancer 17:190-198,2010.
|
| Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow-up of postoperative breast cancer. Ohsumi S, Inoue T, Takashima S,et al. Breast Cancer Res Treat 130:267-272,2011. |
|
| |
|
鶴丸 昌彦 |
順天堂大学がん治療センター長 特任教授 |
| 消化器外科 |
Japanese experience with the surgical treatment of esophageal cancer Masahiko Tsurumaru. 52th Austrian Society of Surgery, Vienna, 2011
|
| Lymphatic invasion according to D2-40 immunostaining is a strong predictor of nodal metastasis in superficial squamous cell carcinoma of the esophagus: Algorithm for risk of nodal metastasis based on lymphatic invasion. N Tomita, TMatsumoto, THayashi, AArakawa, HSonoue, YKajiyama, MTsurumaru. Pathology International.58:282-287,2008 |
Three-Field Esophagectomy: ADULT CHEST SURGERY (Editor: DJ Sugarbaker):171-182,McGraw Hill(2009)
MTsurumaru,YKajiyama,Y Iwanuma, H Udagawa, H Akiyama
(査読なし)
|
|
| |
|
原 純一 |
大阪市立総合医療センター副院長 |
| 小児腫瘍学 |
Hara J. Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol. 2012 Jun;17(3):196-203
|
| Sawada A, Takihara Y, Kim JY, Matsuda-Hashii Y, Tokimasa S, Fujisaki H, Kubota K, Endo H, Onodera T, Ohta H, Ozono K, Hara J. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J Clin Invest. 2003 Dec; 112(11): 1707-13. |
| Hara J, Benedict SH, Yumura K, Ha-Kawa K, Gelfand EW: Rearrangement of variable region T cell receptor gamma genes in acute lymphoblastic leukemia. V gamma gene usage differs in mature and immature T cells. J Clin Invest 1989;83(4):1277-1283 |
|
| |
|
根本 建二 |
山形大学医学部 放射線腫瘍学講座 教授 |
| 放射線治療 |
| Status of radiotherapy in a multidisciplinary cancer board. Ichikawa M, Nemoto K, Miwa M, Ohta I, Nomiya T, Yamakawa M, Itho Y, Fukui T, Yoshioka T. J Radiat Res. 2014;55(2):305-8. |
| Influence of a multidisciplinary cancer board on treatment decisions. Nemoto K, Murakami M, Ichikawa M, Ohta I, Nomiya T, Yamakawa M, Itho Y, Fukui T, Yoshioka T. Int J Clin Oncol. 2013;18(4):574-7 |
| Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks. Nomiya T, Tsuji H, Maruyama K, Toyama S, Suzuki H, Akakura K, Shimazaki J, Nemoto K, Kamada T, Tsujii H; Working Group for Genitourinary Tumors. Br J Cancer. 2014;110(10):2389-95. |
|
